ProShares has always been a fund company that isn’t afraid to introduce new products designed to maximize short-term moves in the market.
Two of their latest ETFs are aiming to capitalize on the red-hot biotech space. On Tuesday, the Proshares UltraPro NASDAQ Biotechnology (NASDAQ: UBIO) and ProShares UltraPro Short NASDAQ Biotechnology (NASDAQ: ZBIO) made their trading debut. These new funds are designed to provide triple-leveraged long and short exposure to a market cap weighted index of biotech companies.
Leveraging ETFs
Leveraged ETFs allow investors to commit smaller amounts of capital in order to produce an enhanced return. These funds are primarily used by aggressive traders and institutional fund managers who are willing to bet big on a specific industry or sector.
/www.benzinga.com/general/biotech/15/06/5618132/proshares-releases-2-new-leveraged-biotech-etfs alt=ProShares Releases 2 New Leveraged Biotech ETFs>Full story available on Benzinga.com
More...